NanoViricides Inc
NNVC1.250USD
+0.040+3.31%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
21.95MMarket Cap
LossP/E TTM
More Details of NanoViricides Inc Company
NanoViricides, Inc. is a clinical-stage company. The Company is engaged in developing a class of drugs that it calls nanoviricides, using a platform technology based on the application of nanomedicine technologies to the complex issues of viral diseases. Its lead drug candidate is NV-387, a broad-spectrum antiviral drug that has demonstrated activity in lethal lung infection animal model studies of Coronavirus (COVID), Respiratory Syncytial Virus, Influenza, Orthopoxvirus model for Smallpox and MPox, and even in a humanized mice model for Measles. It is focused on advancing Phase II clinical trials. Its other advanced drug candidate is NV-HHV-1 for the treatment of Shingles rash. Its NV-CoV-2 and NV-CoV-2-R are drug candidates for the treatment of COVID. Its portfolio also includes NV-HIV-1, a novel mechanism Anti-HIV Drug Candidate. Its other drug candidates include treatment for viral infections, including Dengue viruses, Ebola viruses, among others.
NanoViricides Inc Info
Ticker SymbolNNVC
Company nameNanoViricides, Inc
IPO dateAug 12, 2004
CEODiwan (Anil)
Number of employees7
Security typeOrdinary Share
Fiscal year-endAug 12
Address1 Controls Drive
CitySHELTON
Stock exchangeNASDAQ OMX – NASDAQ Basic Amex
CountryUnited States of America
Postal code06484
Phone12039376137
Websitehttps://www.nanoviricides.com/
Ticker SymbolNNVC
IPO dateAug 12, 2004
CEODiwan (Anil)
Company Executives of NanoViricides Inc
Name
Name/Position
Position
Shareholding
Change
Meeta Vyas
Meeta Vyas
Chief Financial Officer
Chief Financial Officer
7.13K
--
Mr. Brian F. Zucker
Mr. Brian F. Zucker
Independent Director
Independent Director
--
--
Dr. Anil Diwan, Ph.D.
Dr. Anil Diwan, Ph.D.
President, Chief Executive Officer, Executive Chairman of the Board
President, Chief Executive Officer, Executive Chairman of the Board
--
--
Dr. Makarand (Mak) Jawadekar, Ph.D.
Dr. Makarand (Mak) Jawadekar, Ph.D.
Independent Director
Independent Director
--
--
Hon. Theodore Edward (Todd) Rokita, J.D.
Hon. Theodore Edward (Todd) Rokita, J.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Meeta Vyas
Meeta Vyas
Chief Financial Officer
Chief Financial Officer
7.13K
--
Mr. Brian F. Zucker
Mr. Brian F. Zucker
Independent Director
Independent Director
--
--
Dr. Anil Diwan, Ph.D.
Dr. Anil Diwan, Ph.D.
President, Chief Executive Officer, Executive Chairman of the Board
President, Chief Executive Officer, Executive Chairman of the Board
--
--
Dr. Makarand (Mak) Jawadekar, Ph.D.
Dr. Makarand (Mak) Jawadekar, Ph.D.
Independent Director
Independent Director
--
--
Hon. Theodore Edward (Todd) Rokita, J.D.
Hon. Theodore Edward (Todd) Rokita, J.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
3.36%
Theracour Pharma, Inc.
2.62%
Renaissance Technologies LLC
1.17%
Geode Capital Management, L.L.C.
0.89%
BlackRock Institutional Trust Company, N.A.
0.88%
Other
91.08%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
3.36%
Theracour Pharma, Inc.
2.62%
Renaissance Technologies LLC
1.17%
Geode Capital Management, L.L.C.
0.89%
BlackRock Institutional Trust Company, N.A.
0.88%
Other
91.08%
Shareholder Types
Shareholders
Proportion
Investment Advisor
5.16%
Corporation
2.62%
Hedge Fund
1.27%
Investment Advisor/Hedge Fund
1.26%
Individual Investor
0.72%
Bank and Trust
0.15%
Venture Capital
0.06%
Research Firm
0.05%
Other
88.72%
Institutional Shareholding
Updated: Sun, Oct 5
Updated: Sun, Oct 5
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
58
1.34M
7.66%
-219.52K
2025Q2
61
1.84M
11.42%
-370.13K
2025Q1
63
2.05M
12.78%
-124.35K
2024Q4
61
2.03M
12.98%
-23.52K
2024Q3
60
1.91M
13.93%
-126.25K
2024Q2
62
1.91M
16.17%
+50.13K
2024Q1
62
1.74M
14.78%
-267.11K
2023Q4
64
1.76M
14.98%
-214.22K
2023Q3
67
1.72M
14.71%
-264.52K
2023Q2
63
1.75M
15.01%
-221.57K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
510.42K
2.93%
--
--
Jun 30, 2025
Theracour Pharma, Inc.
470.96K
2.7%
--
--
Jun 30, 2025
Renaissance Technologies LLC
111.40K
0.64%
+5.60K
+5.29%
Jun 30, 2025
Geode Capital Management, L.L.C.
157.99K
0.91%
+3.40K
+2.20%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
158.75K
0.91%
--
--
Jun 30, 2025
State Street Investment Management (US)
41.91K
0.24%
--
--
Jun 30, 2025
Jawadakar (Makarand)
41.54K
0.24%
+11.04K
+36.20%
Jun 30, 2025
Rokita (Theodore)
41.01K
0.24%
+11.04K
+36.84%
Jun 30, 2025
Zucker (Brian)
39.79K
0.23%
+11.04K
+38.41%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Dimensional US Core Equity 1 ETF
0%
Dimensional US Core Equity 1 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of NanoViricides Inc?
The top five shareholders of NanoViricides Inc are:
The Vanguard Group, Inc. holds 510.42K shares, accounting for 2.93% of the total shares.
Theracour Pharma, Inc. holds 470.96K shares, accounting for 2.70% of the total shares.
Renaissance Technologies LLC holds 111.40K shares, accounting for 0.64% of the total shares.
Geode Capital Management, L.L.C. holds 157.99K shares, accounting for 0.91% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 158.75K shares, accounting for 0.91% of the total shares.
The Vanguard Group, Inc. holds 510.42K shares, accounting for 2.93% of the total shares.
Theracour Pharma, Inc. holds 470.96K shares, accounting for 2.70% of the total shares.
Renaissance Technologies LLC holds 111.40K shares, accounting for 0.64% of the total shares.
Geode Capital Management, L.L.C. holds 157.99K shares, accounting for 0.91% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 158.75K shares, accounting for 0.91% of the total shares.
What are the top three shareholder types of NanoViricides Inc?
The top three shareholder types of NanoViricides Inc are:
The Vanguard Group, Inc.
Theracour Pharma, Inc.
Renaissance Technologies LLC
The Vanguard Group, Inc.
Theracour Pharma, Inc.
Renaissance Technologies LLC
How many institutions hold shares of NanoViricides Inc (NNVC)?
As of 2025Q3, 58 institutions hold shares of NanoViricides Inc, with a combined market value of approximately 1.34M, accounting for 7.66% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -3.76%.
What is the biggest source of revenue for NanoViricides Inc?
In --, the -- business generated the highest revenue for NanoViricides Inc, amounting to -- and accounting for --% of total revenue.
